R&D channel feed – Endpoints News

R&D channel feed

Finding a winner in VX-445, Vertex hustles CF combo to regulators on both sides of Atlantic

7 years ago

The coming glut? Cancer cell therapy trials are booming as China rivals US on new projects

7 years ago

After generating ASCO fervor, Iovance unveils plans to build $75M cell therapy manufacturing plant

7 years ago

Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?

7 years ago

Novartis burnishes prospects for its big asthma drug with positive PhIII data from a similar treatment

7 years ago

Amicus, Penn expand gene therapy research agreement into five-year collaboration

7 years ago

Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?

7 years ago

As #ASCO19 looms, a top analyst showers some love — and blockbuster status — on Amgen's KRAS killer

7 years ago

Little Cara steers through their first positive PhIII with a ‘breakthrough’ drug and a path to the FDA

7 years ago

A bruised Eli Lilly buys rights to Centrexion's early-stage pain drug for $47.5M upfront

7 years ago

Analysis shows The Medicines Company/Alnylam drug inclisiran safe for renally-impaired patients

7 years ago

Factor VIII levels continue to drop in BioMarin’s 3-year update on hemophilia A gene therapy — but wait...

7 years ago

Brad Loncar's ASCO19 preview: 5 big ideas to watch for at the ultimate cancer show of the year

7 years ago

FDA hits the red light on pivotal trials at Newron, demanding new studies after raising safety concerns

7 years ago

Make that 2 prospective blockbuster approvals in 1 day for Novartis as FDA OKs targeted cancer therapy

7 years ago

Novartis rolls out its next big drug at a record-setting price of $2.12M — let the gene therapy pricing debate begin

7 years ago

Sobered by mounting costs, Dynavax looks to unload I/O, slash jobs and circle wagons around Heplisav

7 years ago

Treading on Nasdaq turf, NYSE cuts listing fees to woo biotech

7 years ago

Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

7 years ago

Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline

7 years ago

Affimed hangs onto Genentech alliance after dropping stranded PhI program as CSO exits

7 years ago

Drug regulators look to harmonize how they tackle innovation

7 years ago

Another gene therapy company launches with VC cash and a CRISPR tech to target toxic RNA

7 years ago

Roche's Chugai to set up new $1B+ lab in Yokohama, consolidating R&D

7 years ago

First page Previous page 243 244 245246247 248 249 Next page Last page